Safety, Tolerability, and Pharmacokinetics of C2N-8E12 in Subjects With Progressive Supranuclear Palsy

NCT02494024 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Supranuclear Palsy

Interventions

DRUG: Single dose C2N-8E12
DRUG: Single dose placebo

Sponsor

C2N Diagnostics